Summary of Study ST001720

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR001053. The data can be accessed directly via it's Project DOI: 10.21228/M8KQ59 This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001720
Study TitleMetabolomics Analysis of ACTG Cohort -Update (part-II)
Study TypeMetabolomics Analysis
Study SummaryGlobal metabolomics analysis of ACTG cohort
The Wistar Institute
Last NameAbdel-Mohsen
First NameMohamed
Address3601 Spruce St, Philadelphia, PA 19104
Submit Date2021-01-07
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2021-05-25
Release Version1
Mohamed Abdel-Mohsen Mohamed Abdel-Mohsen application/zip

Select appropriate tab below to view additional metadata details:


Collection ID:CO001790
Collection Summary:Analyses were performed from banked plasma samples of two different cohorts that underwent analytical treatment interruption (ATI): (1) Philadelphia Cohort and (2) ACTG cohort. In the Philadelphia cohort, HIV+ individuals on suppressive ART underwent an open-ended ATI without concurrent immunomodulatory agents. The ACTG cohort combined 74 HIV-infected ART-suppressed participants who underwent ATI from six ACTG ATI studies (ACTG 371,28 A5024,29 A5068,30 A5170,31 A5187,32 and A519733). 27 of these 74 individuals exhibited a PTC phenotype post-ATI, i.e. these individuals remained off ART for ≥24 weeks post-treatment interruption, sustained virologic control for at least 24 weeks, maintained viral load (VL) ≤400 copies for at least 2/3 of time points, had plasma drug level testing performed, and had no evidence of spontaneous control pre-ART. The remaining 47 cohort members were non-controllers (NCs) who exhibited virologic rebound before meeting PTC criteria. These two groups were matched for gender, age, % treated at the early stage of HIV infection, ART duration, pre-ATI CD4 count, and ethnicity. All analyses were performed on samples collected immediately before ATI in both cohorts.
Sample Type:Blood (plasma)